#BEGIN_DRUGCARD DB03740

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C8H15NO6

# Chemical_IUPAC_Name:
N-[(2R,3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
The N-acetyl derivative of glucosamine. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose

# HET_ID:
NDG

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5-,6+,7-,8-/m1/s1

# InChI_Key:
InChIKey=OVRNDRQMDRJTHS-JAJWTYFOSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3740

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
221.2078

# Molecular_Weight_Mono:
221.089937217

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1W1A

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.6

# Predicted_LogS:
0.06

# Predicted_Water_Solubility:
2.54e+02 g/l

# Primary_Accession_No:
DB03740

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
440552

# PubChem_Substance_ID:
46508699

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02319

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:34 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE004091

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
lecB

# Drug_Target_1_Gene_Sequence:
>348 bp
ATGGCAACACAAGGAGTGTTCACCCTTCCCGCCAACACCCGGTTCGGCGTCACCGCCTTC
GCCAACTCGTCCGGAACCCAGACGGTGAACGTGCTGGTCAACAACGAGACGGCCGCGACC
TTCAGCGGGCAAAGCACCAATAACGCCGTCATCGGCACCCAGGTGCTCAACTCCGGCAGC
AGTGGCAAGGTACAGGTCCAGGTCAGCGTCAACGGCCGCCCCTCGGATCTGGTCTCGGCA
CAGGTAATCCTGACCAACGAGCTGAACTTCGCCCTGGTCGGCTCTGAAGACGGCACCGAC
AACGACTACAACGACGCCGTCGTGGTGATCAACTGGCCGCTCGGCTAG

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10984043	Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature. 2000 Aug 31;406(6799):959-64.
12415289	Mitchell E, Houles C, Sudakevitz D, Wimmerova M, Gautier C, Perez S, Wu AM, Gilboa-Garber N, Imberty A: Structural basis for oligosaccharide-mediated adhesion of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. Nat Struct Biol. 2002 Dec;9(12):918-21.
12909014	Loris R, Tielker D, Jaeger KE, Wyns L: Structural basis of carbohydrate recognition by the lectin LecB from Pseudomonas aeruginosa. J Mol Biol. 2003 Aug 22;331(4):861-70.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4666

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
11863

# Drug_Target_1_Name:
Fucose-binding lectin PA-IIL

# Drug_Target_1_Number_of_Residues:
115

# Drug_Target_1_PDB_ID:
1W8H

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07472	PA-IIL

# Drug_Target_1_Protein_Sequence:
>Fucose-binding lectin PA-IIL
MATQGVFTLPANTRFGVTAFANSSGTQTVNVLVNNETAATFSGQSTNNAVIGTQVLNSGS
SGKVQVQVSVNGRPSDLVSAQVILTNELNFALVGSEDGTDNDYNDAVVVINWPLG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9HYN5

# Drug_Target_1_SwissProt_Name:
Q9HYN5_PSEAE

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
3.83

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
TM:Virion

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
env

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Involved in structural molecule activity

# Drug_Target_2_General_References:
3497350	Franchini G, Gurgo C, Guo HG, Gallo RC, Collalti E, Fargnoli KA, Hall LF, Wong-Staal F, Reitz MS Jr: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature. 1987 Aug 6-12;328(6130):539-43.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4787

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
101132

# Drug_Target_2_Name:
Envelope glycoprotein gp160

# Drug_Target_2_Number_of_Residues:
881

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00516	GP120
PF00517	GP41

# Drug_Target_2_Protein_Sequence:
>Envelope glycoprotein gp160
MGCLGNQLLIAILLLSVYGIYCTQYVTVFYGVPAWRNATIPLFCATKNRDTWGTTQCLPD
NGDYSELALNVTESFDAWENTVTEQAIEDVWQLFETSIKPCVKLSPLCITMRCNKSETDR
WGLTKSSTTITTAAPTSAPVSEKIDMVNETSSCIAQNNCTGLEQEQMISCKFTMTGLKRD
KTKEYNETWYSTDLVCEQGNSTDNESRCYMNHCNTSVIQESCDKHYWDTIRFRYCAPPGY
ALLRCNDTNYSGFMPKCSKVVVSSCTRMMETQTSTWFGFNGTRAENRTYIYWHGRDNRTI
ISLNKYYNLTMKCRRPGNKTVLPVTIMSGLVFHSQPLTDRPKQAWCWFGGKWKDAIKEVK
QTIVKHPRYTGTNNTDKINLTAPGGGDPEVTFMWTNCRGEFLYCKMNWFLNWVEDRDVTT
QRPKERHRRNYVPCHIRQIINTWHKVGKNVYLPPREGDLTCNSTVTSLIANIDWTDGNQT
SITMSAEVAELYRLELGDYKLVEITPIGLAPTDVKRYTTGGTSRNKRGVFVLGFLGFLAT
AGSAMGAASFRLTAQSRTLLAGIVQQQQQLLGVVKRQQELLRLTVWGTKNLQTRVTAIEK
YLEDQAQLNAWGCAFRQVCHTTVPWPNASLTPDWNNDTWQEWERKVDFLEENITALLEEA
QIQQEKNMYELQKLNSWDVFGNWFDLASWIKYIQYGIYVVVGVILLRIVIYIVQMLAKLR
QGYRPVFSSPPSYFQXTHTQQDPALPTREGKEGDGGEGGGNSSWPWQIEYIHFLIRQLIR
LLTWLFSNCRTLLSRAYQILQPILQRLSATLRRIREVLRTELTYLQYGWSYFHEAVQAGW
RSATETLAGAWGDLWETLRRGGRWILAIPRRIRQGLELTLL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-19

# Drug_Target_2_Specific_Function:
Allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves (By similarity)

# Drug_Target_2_SwissProt_ID:
P05884

# Drug_Target_2_SwissProt_Name:
ENV_SIVMK

# Drug_Target_2_Synonyms:
Env polyprotein
Envelope glycoprotein gp160 precursor

# Drug_Target_2_Theoretical_pI:
8.40

# Drug_Target_2_Transmembrane_Regions:
697-717

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
IGHG1

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
IGHG1

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
1002129	Dreker L, Schwarz J, Reichel W, Hilschmann N: [Rule of antibody structure. the primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie), I: Purification and characterization of the protein, the L- and H-chains, the cyanogenbromide cleavage products, and the disulfide bridges (author's transl)] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1515-40.
4923144	Gall WE, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. X. Intrachain disulfide bonds. Biochemistry. 1970 Aug 4;9(16):3188-96.
5489771	Cunningham BA, Rutishauser U, Gall WE, Gottlieb PD, Waxdal MJ, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. VII. Amino acid sequence of heavy-chain cyanogen bromide fragments H1-H4. Biochemistry. 1970 Aug 4;9(16):3161-70.
5530842	Rutishauser U, Cunningham BA, Bennett C, Konigsberg WH, Edelman GM: The covalent structure of a human gamma G-immunoglobulin. 8. Amino acid sequence of heavy-chain cyanogen bromide fragments H5-H7. Biochemistry. 1970 Aug 4;9(16):3171-81.
6287432	Ellison JW, Berson BJ, Hood LE: The nucleotide sequence of a human immunoglobulin C gamma1 gene. Nucleic Acids Res. 1982 Jul 10;10(13):4071-9.
6884994	Schmidt WE, Jung HD, Palm W, Hilschmann N: [Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I] Hoppe Seylers Z Physiol Chem. 1983 Jun;364(6):713-47.
7236608	Deisenhofer J: Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981 Apr 28;20(9):2361-70.
826475	Ponstingl H, Hilschmann N: [The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure] Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1571-604.

# Drug_Target_3_HGNC_ID:
HGNC:5525

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4785

# Drug_Target_3_Locus:
14q32.33

# Drug_Target_3_Molecular_Weight:
36106

# Drug_Target_3_Name:
Ig gamma-1 chain C region

# Drug_Target_3_Number_of_Residues:
330

# Drug_Target_3_PDB_ID:
1HZH

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF07654	C1-set

# Drug_Target_3_Protein_Sequence:
>Ig gamma-1 chain C region
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P01857

# Drug_Target_3_SwissProt_Name:
IGHG1_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
8.31

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cell membrane
single-pass type I membrane protein. Processed form:Secreted protein. A soluble form

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ACE

# Drug_Target_4_GenBank_ID_Gene:
J04144

# Drug_Target_4_GenBank_ID_Protein:
178286

# Drug_Target_4_GeneCard_ID:
ACE

# Drug_Target_4_Gene_Name:
ACE

# Drug_Target_4_Gene_Sequence:
>3921 bp
ATGGGGGCCGCCTCGGGCCGCCGGGGGCCGGGGCTGCTGCTGCCGCTGCCGCTGCTGTTG
CTGCTGCCGCCGCAGCCCGCCCTGGCGTTGGACCCCGGGCTGCAGCCCGGCAACTTTTCT
GCTGACGAGGCCGGGGCGCAGCTCTTCGCGCAGAGCTACAACTCCAGCGCCGAACAGGTG
CTGTTCCAGAGCGTGGCCGCCAGCTGGGCGCACGACACCAACATCACCGCGGAGAATGCA
AGGCGCCAGGAGGAAGCAGCCCTGCTCAGCCAGGAGTTTGCGGAGGCCTGGGGCCAGAAG
GCCAAGGAGCTGTATGAACCGATCTGGCAGAACTTCACGGACCCGCAGCTGCGCAGGATC
ATCGGAGCTGTGCGAACCCTGGGCTCTGCCAACCTGCCCCTGGCTAAGCGGCAGCAGTAC
AACGCCCTGCTAAGCAACATGAGCAGGATCTACTCCACCGCCAAGGTCTGCCTCCCCAAC
AAGACTGCCACCTGCTGGTCCCTGGACCCAGATCTCACCAACATCCTGGCTTCCTCGCGA
AGCTACGCCATGCTCCTGTTTGCCTGGGAGGGCTGGCACAACGCTGCGGGCATCCCGCTG
AAACCGCTGTACGAGGATTTCACTGCCCTCAGCAATGAAGCCTACAAGCAGGACGGCTTC
ACAGACACGGGGGCCTACTGGCGCTCCTGGTACAACTCCCCCACCTTCGAGGACGATCTG
GAACACCTCTACCAACAGCTAGAGCCCCTCTACCTGAACCTCCATGCCTTCGTCCGCCGC
GCACTGCATCGCCGATACGGAGACAGATACATCAACCTCAGGGGACCCATCCCTGCTCAT
CTGCTGGGAGACATGTGGGCCCAGAGCTGGGAAAACATCTACGACATGGTGGTGCCTTTC
CCAGACAAGCCCAACCTCGATGTCACCAGTACTATGCTGCAGCAGGGCTGGAACGCCACG
CACATGTTCCGGGTGGCAGAGGAGTTCTTCACCTCCCTGGAGCTCTCCCCCATGCCTCCC
GAGTTCTGGGAAGGGTCGATGCTGGAGAAGCCGGCCGACGGGCGGGAAGTGGTGTGCCAC
GCCTCGGCTTGGGACTTCTACAACAGGAAAGACTTCAGGATCAAGCAGTGCACACGGGTC
ACGATGGACCAGCTCTCCACAGTGCACCATGAGATGGGCCATATACAGTACTACCTGCAG
TACAAGGATCTGCCCGTCTCCCTGCGTCGGGGGGCCAACCCCGGCTTCCATGAGGCCATT
GGGGACGTGCTGGCGCTCTCGGTCTCCACTCCTGAACATCTGCACAAAATCGGCCTGCTG
GACCGTGTCACCAATGACACGGAAAGTGACATCAATTACTTGCTAAAAATGGCACTGGAA
AAAATTGCCTTCCTGCCCTTTGGCTACTTGGTGGACCAGTGGCGCTGGGGGGTCTTTAGT
GGGCGTACCCCCCCTTCCCGCTACAACTTCGACTGGTGGTATCTTCGAACCAAGTATCAG
GGGATCTGTCCTCCTGTTACCCGAAACGAAACCCACTTTGATGCTGGAGCTAAGTTTCAT
GTTCCAAATGTGACACCATACATCAGGTACTTTGTGAGTTTTGTCCTGCAGTTCCAGTTC
CATGAAGCCCTGTGCAAGGAGGCAGGCTATGAGGGCCCACTGCACCAGTGTGACATCTAC
CGGTCCACCAAGGCAGGGGCCAAGCTCCGGAAGGTGCTGCAGGCTGGCTCCTCCAGGCCC
TGGCAGGAGGTGCTGAAGGACATGGTCGGCTTAGATGCCCTGGATGCCCAGCCGCTGCTC
AAGTACTTCCAGCCAGTCACCCAGTGGCTGCAGGAGCAGAACCAGCAGAACGGCGAGGTC
CTGGGCTGGCCCGAGTACCAGTGGCACCCGCCGTTGCCTGACAACTACCCGGAGGGCATA
GACCTGGTGACTGATGAGGCTGAGGCCAGCAAGTTTGTGGAGGAATATGACCGGACATCC
CAGGTGGTGTGGAACGAGTATGCCGAGGCCAACTGGAACTACAACACCAACATCACCACA
GAGACCAGCAAGATTCTGCTGCAGAAGAACATGCAAATAGCCAACCACACCCTGAAGTAC
GGCACCCAGGCCAGGAAGTTTGATGTGAACCAGTTGCAGAACACCACTATCAAGCGGATC
ATAAAGAAGGTTCAGGACCTAGAACGGGCAGCGCTGCCTGCCCAGGAGCTGGAGGAGTAC
AACAAGATCCTGTTGGATATGGAAACCACCTACAGCGTGGCCACTGTGTGCCACCCGAAT
GGCAGCTGCCTGCAGCTCGAGCCAGATCTGACGAATGTGATGGCCACATCCCGGAAATAT
GAAGACCTGTTATGGGCATGGGAGGGCTGGCGAGACAAGGCGGGGAGAGCCATCCTCCAG
TTTTACCCGAAATACGTGGAACTCATCAACCAGGCTGCCCGGCTCAATGGCTATGTAGAT
GCAGGGGACTCGTGGAGGTCTATGTACGAGACACCATCCCTGGAGCAAGACCTGGAGCGG
CTCTTCCAGGAGCTGCAGCCACTCTACCTCAACCTGCATGCCTACGTGCGCCGGGCCCTG
CACCGTCACTACGGGGCCCAGCACATCAACCTGGAGGGGCCCATTCCTGCTCACCTGCTG
GGGAACATGTGGGCGCAGACCTGGTCCAACATCTATGACTTGGTGGTGCCCTTCCCTTCA
GCCCCCTCGATGGACACCACAGAGGCTATGCTAAAGCAGGGCTGGACGCCCAGGAGGATG
TTTAAGGAGGCTGATGATTTCTTCACCTCCCTGGGGCTGCTGCCCGTGCCTCCTGAGTTC
TGGAACAAGTCGATGCTGGAGAAGCCAACCGACGGGCGGGAGGTGGTCTGCCACGCCTCG
GCCTGGGACTTCTACAACGGCAAGGACTTCCGGATCAAGCAGTGCACCACCGTGAACTTG
GAGGACCTGGTGGTGGCCCACCACGAAATGGGCCACATCCAGTATTTCATGCAGTACAAA
GACTTACCTGTGGCCTTGAGGGAGGGTGCCAACCCCGGCTTCCATGAGGCCATTGGGGAC
GTGCTAGCCCTCTCAGTGTCTACGCCCAAGCACCTGCACAGTCTCAACCTGCTGAGCAGT
GAGGGTGGCAGCGACGAGCATGACATCAACTTTCTGATGAAGATGGCCCTTGACAAGATC
GCCTTTATCCCCTTCAGCTACCTCGTCGATCAGTGGCGCTGGAGGGTATTTGATGGAAGC
ATCACCAAGGAGAACTATAACCAGGAGTGGTGGAGCCTCAGGCTGAAGTACCAGGGCCTC
TGCCCCCCAGTGCCCAGGACTCAAGGTGACTTTGACCCAGGGGCCAAGTTCCACATTCCT
TCTAGCGTGCCTTACATCAGGTACTTTGTCAGCTTCATCATCCAGTTCCAGTTCCACGAG
GCACTGTGCCAGGCAGCTGGCCACACGGGCCCCCTGCACAAGTGTGACATCTACCAGTCC
AAGGAGGCCGGGCAGCGCCTGGCGACCGCCATGAAGCTGGGCTTCAGTAGGCCGTGGCCG
GAAGCCATGCAGCTGATCACGGGCCAGCCCAACATGAGCGCCTCGGCCATGTTGAGCTAC
TTCAAGCCGCTGCTGGACTGGCTCCGCACGGAGAACGAGCTGCATGGGGAGAAGCTGGGC
TGGCCGCAGTACAACTGGACGCCGAACTCCGCTCGCTCAGAAGGGCCCCTCCCAGACAGC
GGCCGCGTCAGCTTCCTGGGCCTGGACCTGGATGCGCAGCAGGCCCGCGTGGGCCAGTGG
CTGCTGCTCTTCCTGGGCATCGCCCTGCTGGTAGCCACCCTGGGCCTCAGCCAGCGGCTC
TTCAGCATCCGCCACCGCAGCCTCCACCGGCACTCCCACGGGCCCCAGTTCGGCTCCGAG
GTGGAGCTGAGACACTCCTGA

# Drug_Target_4_General_Function:
Involved in metallopeptidase activity

# Drug_Target_4_General_References:
10319862	Rieder MJ, Taylor SL, Clark AG, Nickerson DA: Sequence variation in the human angiotensin converting enzyme. Nat Genet. 1999 May;22(1):59-62.
10391210	Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999 Jul;22(3):239-47.
10924499	Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000 Oct 27;275(43):33238-43.
10969042	Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep 1;87(5):E1-9.
12459472	Harmer D, Gilbert M, Borman R, Clark KL: Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002 Dec 4;532(1-2):107-10.
1649623	Ehlers MR, Riordan JF: Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry. 1991 Jul 23;30(29):7118-26.
2558109	Takeuchi K, Shimizu T, Ohishi N, Seyama Y, Takaku F, Yotsumoto H: Purification of human lung angiotensin-converting enzyme by high-performance liquid chromatography: properties and N-terminal amino acid sequence. J Biochem (Tokyo). 1989 Sep;106(3):442-5.
2849100	Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P: Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9386-90.

# Drug_Target_4_HGNC_ID:
HGNC:2707

# Drug_Target_4_HPRD_ID:
00108

# Drug_Target_4_ID:
244

# Drug_Target_4_Locus:
17q23.3

# Drug_Target_4_Molecular_Weight:
149716

# Drug_Target_4_Name:
Angiotensin-converting enzyme

# Drug_Target_4_Number_of_Residues:
1306

# Drug_Target_4_PDB_ID:
1UZF

# Drug_Target_4_Pathway:
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Enalapril Pathway	SMP00148
Fosinopril Pathway	SMP00149
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157

# Drug_Target_4_Pfam_Domain_Function:
PF01401	Peptidase_M2

# Drug_Target_4_Protein_Sequence:
>Angiotensin-converting enzyme, somatic isoform precursor
MGAASGRRGPGLLLPLPLLLLLPPQPALALDPGLQPGNFSADEAGAQLFAQSYNSSAEQV
LFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQNFTDPQLRRI
IGAVRTLGSANLPLAKRQQYNALLSNMSRIYSTAKVCLPNKTATCWSLDPDLTNILASSR
SYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDL
EHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPF
PDKPNLDVTSTMLQQGWNATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCH
ASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAI
GDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFS
GRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQF
HEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLQAGSSRPWQEVLKDMVGLDALDAQPLL
KYFQPVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDRTS
QVVWNEYAEANWNYNTNITTETSKILLQKNMQIANHTLKYGTQARKFDVNQLQNTTIKRI
IKKVQDLERAALPAQELEEYNKILLDMETTYSVATVCHPNGSCLQLEPDLTNVMATSRKY
EDLLWAWEGWRDKAGRAILQFYPKYVELINQAARLNGYVDAGDSWRSMYETPSLEQDLER
LFQELQPLYLNLHAYVRRALHRHYGAQHINLEGPIPAHLLGNMWAQTWSNIYDLVVPFPS
APSMDTTEAMLKQGWTPRRMFKEADDFFTSLGLLPVPPEFWNKSMLEKPTDGREVVCHAS
AWDFYNGKDFRIKQCTTVNLEDLVVAHHEMGHIQYFMQYKDLPVALREGANPGFHEAIGD
VLALSVSTPKHLHSLNLLSSEGGSDEHDINFLMKMALDKIAFIPFSYLVDQWRWRVFDGS
ITKENYNQEWWSLRLKYQGLCPPVPRTQGDFDPGAKFHIPSSVPYIRYFVSFIIQFQFHE
ALCQAAGHTGPLHKCDIYQSKEAGQRLATAMKLGFSRPWPEAMQLITGQPNMSASAMLSY
FKPLLDWLRTENELHGEKLGWPQYNWTPNSARSEGPLPDSGRVSFLGLDLDAQQARVGQW
LLLFLGIALLVATLGLSQRLFSIRHRSLHRHSHGPQFGSEVELRHS

# Drug_Target_4_Reaction:
Release of a C-terminal dipeptide, oligopeptide!Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of angiotensin I to angiotensin II, with increase in vasoconstrictor activity, but no action on angiotensin II COFACTOR Zinc INHIBITOR (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]g lycine; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]- (S)-alanine; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxoprolyl ]glycine benzyl ester; (S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(acetylthio)methyl-1-oxoprolyl ]-(S)-alanine benzyl ester EFFECTOR Chloride

# Drug_Target_4_Signals:
1-29

# Drug_Target_4_Specific_Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator

# Drug_Target_4_SwissProt_ID:
P12821

# Drug_Target_4_SwissProt_Name:
ACE_HUMAN

# Drug_Target_4_Synonyms:
Angiotensin-converting enzyme, somatic isoform precursor
CD143 antigen
Dipeptidyl carboxypeptidase I
EC 3.4.15.1
Kininase II

# Drug_Target_4_Theoretical_pI:
6.36

# Drug_Target_4_Transmembrane_Regions:
1260-1276

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
ACHE

# Drug_Target_5_GenBank_ID_Gene:
M55040

# Drug_Target_5_GenBank_ID_Protein:
177975

# Drug_Target_5_GeneCard_ID:
ACHE

# Drug_Target_5_Gene_Name:
ACHE

# Drug_Target_5_Gene_Sequence:
>1845 bp
ATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC
CTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG
GTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC
TCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA
CCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC
TACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC
CGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA
TCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC
TTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG
AACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC
AATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC
TTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG
GGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC
GGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG
CAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG
GTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG
CCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT
GACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT
GTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC
AACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG
GTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG
GACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC
CCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC
TTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC
GAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG
AAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC
AATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG
TACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC
GCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG
GAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC
CAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA

# Drug_Target_5_General_Function:
Lipid transport and metabolism

# Drug_Target_5_General_References:
11053835	Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, Silman I, Sussman JL: Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1385-94.
11239002	Wilson MD, Riemer C, Martindale DW, Schnupf P, Boright AP, Cheung TL, Hardy DM, Schwartz S, Scherer SW, Tsui LC, Miller W, Koop BF: Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res. 2001 Mar 15;29(6):1352-65.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1517212	Shafferman A, Kronman C, Flashner Y, Leitner M, Grosfeld H, Ordentlich A, Gozes Y, Cohen S, Ariel N, Barak D, et al.: Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem. 1992 Sep 5;267(25):17640-8.
1748670	Velan B, Grosfeld H, Kronman C, Leitner M, Gozes Y, Lazar A, Flashner Y, Marcus D, Cohen S, Shafferman A: The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem. 1991 Dec 15;266(35):23977-84.
2263619	Soreq H, Ben-Aziz R, Prody CA, Seidman S, Gnatt A, Neville L, Lieman-Hurwitz J, Lev-Lehman E, Ginzberg D, Lipidot-Lifson Y, et al.: Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9688-92.
2714437	Chhajlani V, Derr D, Earles B, Schmell E, August T: Purification and partial amino acid sequence analysis of human erythrocyte acetylcholinesterase. FEBS Lett. 1989 Apr 24;247(2):279-82.
8299725	Karpel R, Ben Aziz-Aloya R, Sternfeld M, Ehrlich G, Ginzberg D, Tarroni P, Clementi F, Zakut H, Soreq H: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp Cell Res. 1994 Feb;210(2):268-77.
8488842	Bartels CF, Zelinski T, Lockridge O: Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet. 1993 May;52(5):928-36.
9640563	Felder CE, Botti SA, Lifson S, Silman I, Sussman JL: External and internal electrostatic potentials of cholinesterase models. J Mol Graph Model. 1997 Oct;15(5):318-27, 335-7.

# Drug_Target_5_HGNC_ID:
HGNC:108

# Drug_Target_5_HPRD_ID:
00010

# Drug_Target_5_ID:
474

# Drug_Target_5_Locus:
7q22

# Drug_Target_5_Molecular_Weight:
67797

# Drug_Target_5_Name:
Acetylcholinesterase

# Drug_Target_5_Number_of_Residues:
614

# Drug_Target_5_PDB_ID:
1F8U

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00135	COesterase

# Drug_Target_5_Protein_Sequence:
>Acetylcholinesterase precursor
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV
SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN
RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM
NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV
GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL
VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG
VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE
DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY
EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ
YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN
QFDHYSKQDRCSDL

# Drug_Target_5_Reaction:
acetylcholine + H2O = choline + acetate

# Drug_Target_5_Signals:
1-31

# Drug_Target_5_Specific_Function:
Rapidly hydrolyzes choline released into the synapse

# Drug_Target_5_SwissProt_ID:
P22303

# Drug_Target_5_SwissProt_Name:
ACES_HUMAN

# Drug_Target_5_Synonyms:
AChE
Acetylcholinesterase precursor
EC 3.1.1.7

# Drug_Target_5_Theoretical_pI:
6.24

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Lysosome
lumenal side. Note=Interaction with sapon
lysosomal membrane
peripheral membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
GBA

# Drug_Target_6_GenBank_ID_Gene:
M16328

# Drug_Target_6_GenBank_ID_Protein:
183008

# Drug_Target_6_GeneCard_ID:
GBA

# Drug_Target_6_Gene_Name:
GBA

# Drug_Target_6_Gene_Sequence:
>1551 bp
ATGGCTGGCAGCCTCACAGGTTTGCTTCTACTTCAGGCAGTGTCGTGGGCATCAGGTGCC
CGCCCCTGCATCCCTAAAAGCTTCGGCTACAGCTCGGTGGTGTGTGTCTGCAATGCCACA
TACTGTGACTCCTTTGACCCCCCGACCTTTCCTGCCCTTGGTACCTTCAGCCGCTATGAG
AGTACACGCAGTGGGCGACGGATGGAGCTGAGTATGGGGCCCATCCAGGCTAATCACACG
GGCACAGGCCTGCTACTGACCCTGCAGCCAGAACAGAAGTTCCAGAAAGTGAAGGGATTT
GGAGGGGCCATGACAGATGCTGCTGCTCTCAACATCCTTGCCCTGTCACCCCCTGCCCAA
AATTTGCTACTTAAATCGTACTTCTCTGAAGAAGGAATCGGATATAACATCATCCGGGTA
CCCATGGCCAGCTGTGACTTCTCCATCCGCACCTACACCTATGCAGACACCCCTGATGAT
TTCCAGTTGCACAACTTCAGCCTCCCAGAGGAAGATACCAAGCTCAAGATACCCCTGATT
CACCGAGCCCTGCAGTTGGCCCAGCGTCCCGTTTCACTCCTTGCCAGCCCCTGGACATCA
CCCACTTGGCTCAAGACCAATGGAGCGGTGAATGGGAAGGGGTCACTCAAGGGACAGCCC
GGAGACATCTACCACCAGACCTGGGCCAGATACTTTGTGAAGTTCCTGGATGCCTATGCT
GAGCACAAGTTACAGTTCTGGGCAGTGACAGCTGAAAATGAGCCTTCTGCTGGGCTGTTG
AGTGGATACCCCTTCCAGTGCCTGGGCTTCACCCCTGAACATCAGCGAGACTTCATTGCC
CGTGACCTAGGTCCTACCCTCGCCAACAGTACTCACCACAATGTCCGCCTACTCATGCTG
GATGACCAACGCTTGCTGCTGCCCCACTGGGCAAAGGTGGTACTGACAGACCCAGAAGCA
GCTAAATATGTTCATGGCATTGCTGTACATTGGTACCTGGACTTTCTGGCTCCAGCCAAA
GCCACCCTAGGGGAGACACACCGCCTGTTCCCCAACACCATGCTCTTTGCCTCAGAGGCC
TGTGTGGGCTCCAAGTTCTGGGAGCAGAGTGTGCGGCTAGGCTCCTGGGATCGAGGGATG
CAGTACAGCCACAGCATCATCACGAACCTCCTGTACCATGTGGTCGGCTGGACCGACTGG
AACCTTGCCCTGAACCCCGAAGGAGGACCCAATTGGGTGCGTAACTTTGTCGACAGTCCC
ATCATTGTAGACATCACCAAGGACACGTTTTACAAACAGCCCATGTTCTACCACCTTGGC
CACTTCAGCAAGTTCATTCCTGAGGGCTCCCAGAGAGTGGGGCTGGTTGCCAGTCAGAAG
AACGACCTGGACGCAGTGGCACTGATGCATCCCGATGGCTCTGCTGTTGTGGTCGTGCTA
AACCGCTCCTCTAAGGATGTGCCTCTTACCATCAAGGATCCTGCTGTGGGCTTCCTGGAG
ACAATCTCACCTGGCTACTCCATTCACACCTACCTGTGGCATCGCCAGTGA

# Drug_Target_6_General_Function:
Involved in glucosylceramidase activity

# Drug_Target_6_General_References:
10340647	Wasserstein MP, Martignetti JA, Zeitlin R, Lumerman H, Solomon M, Grace ME, Desnick RJ: Type 1 Gaucher disease presenting with extensive mandibular lytic lesions: identification and expression of a novel acid beta-glucosidase mutation. Am J Med Genet. 1999 Jun 4;84(4):334-9.
10352942	Stone DL, van Diggelen OP, de Klerk JB, Gaillard JL, Niermeijer MF, Willemsen R, Tayebi N, Sidransky E: Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease? Eur J Hum Genet. 1999 May-Jun;7(4):505-9.
10360404	Choy FY, Wong K, Shi HP: Glucocerebrosidase mutations among Chinese neuronopathic and non-neuronopathic Gaucher disease patients. Am J Med Genet. 1999 Jun 11;84(5):484-6.
10447266	Sarria AJ, Giraldo P, Perez-Calvo JI, Pocovi M: Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher disease patients. Mutation in brief no. 251. Online. Hum Mutat. 1999;14(1):88.
10527671	Tayebi N, Stone DL, Sidransky E: Type 2 gaucher disease: an expanding phenotype. Mol Genet Metab. 1999 Oct;68(2):209-19.
10649495	Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E: Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat. 2000;15(2):181-8.
10744424	Hodanova K, Hrebicek M, Cervenkova M, Mrazova L, Veprekova L, Zemen J: Analysis of the beta-glucocerebrosidase gene in Czech and Slovak Gaucher patients: mutation profile and description of six novel mutant alleles. Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):287-98.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
1572652	Beutler E, West C, Gelbart T: Polymorphisms in the human glucocerebrosidase gene. Genomics. 1992 Apr;12(4):795-800.
1972019	Hong CM, Ohashi T, Yu XJ, Weiler S, Barranger JA: Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol. 1990 May;9(4):233-41.
1974409	Beutler E, Gelbart T: Gaucher disease associated with a unique KpnI restriction site: identification of the amino-acid substitution. Ann Hum Genet. 1990 May;54(Pt 2):149-53.
2914709	Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E: The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 1989 Jan;4(1):87-96.
3001061	Tsuji S, Choudary PV, Martin BM, Winfield S, Barranger JA, Ginns EI: Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J Biol Chem. 1986 Jan 5;261(1):50-3.
3353383	Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI: Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2349-52.
3359914	Reiner O, Wigderson M, Horowitz M: Structural analysis of the human glucocerebrosidase genes. DNA. 1988 Mar;7(2):107-16.
3456607	Dinur T, Osiecki KM, Legler G, Gatt S, Desnick RJ, Grabowski GA: Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1660-4.
3687939	Sorge JA, West C, Kuhl W, Treger L, Beutler E: The human glucocerebrosidase gene has two functional ATG initiator codons. Am J Hum Genet. 1987 Dec;41(6):1016-24.
3864160	Sorge J, West C, Westwood B, Beutler E: Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7289-93.
6091633	Ginns EI, Choudary PV, Martin BM, Winfield S, Stubblefield B, Mayor J, Merkle-Lehman D, Murray GJ, Bowers LA, Barranger JA: Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. Biochem Biophys Res Commun. 1984 Sep 17;123(2):574-80.
7627184	Cormand B, Vilageliu L, Burguera JM, Balcells S, Gonzalez-Duarte R, Grinberg D, Chabas A: Gaucher disease in Spanish patients: analysis of eight mutations. Hum Mutat. 1995;5(4):303-9.
7627192	Choy FY, Wei C: Identification of a new mutation (P178S) in an African-American patient with type 2 Gaucher disease. Hum Mutat. 1995;5(4):345-7.
7916532	Choy FY, Wei C, Applegarth DA, McGillivray BC: DNA analysis of an uncommon missense mutation in a Gaucher disease patient of Jewish-Polish-Russian descent. Am J Med Genet. 1994 Jun 1;51(2):156-60.
8076951	Tuteja R, Tuteja N, Lilliu F, Bembi B, Galanello R, Cao A, Baralle FE: Y418C: a novel mutation in exon 9 of the glucocerebrosidase gene of a patient with Gaucher disease creates a new Bgl I site. Hum Genet. 1994 Sep;94(3):314-5.
8112750	Beutler E, Gelbart T: Two new Gaucher disease mutations. Hum Genet. 1994 Feb;93(2):209-10.
8118460	Horowitz M, Zimran A: Mutations causing Gaucher disease. Hum Mutat. 1994;3(1):1-11.
8294033	Imai K, Nakamura M, Yamada M, Asano A, Yokoyama S, Tsuji S, Ginns EI: A novel transcript from a pseudogene for human glucocerebrosidase in non-Gaucher disease cells. Gene. 1993 Dec 22;136(1-2):365-8.
8432537	Beutler E, Gelbart T, West C: Identification of six new Gaucher disease mutations. Genomics. 1993 Jan;15(1):203-5.
8780099	Seeman PJ, Finckh U, Hoppner J, Lakner V, Liebisch I, Grau G, Rolfs A: Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease. Neurology. 1996 Apr;46(4):1102-7.
8790604	Beutler E, Demina A, Gelbart T: Glucocerebrosidase mutations in Gaucher disease. Mol Med. 1994 Nov;1(1):82-92.
8829654	Kim JW, Liou BB, Lai MY, Ponce E, Grabowski GA: Gaucher disease: identification of three new mutations in the Korean and Chinese (Taiwanese) populations. Hum Mutat. 1996;7(3):214-8.
8829663	Cormand B, Vilageliu L, Balcells S, Gonzalez-Duarte R, Chabas A, Grinberg D: Two novel (1098insA and Y313H) and one rare (R359Q) mutations detected in exon 8 of the beta-glucocerebrosidase gene in Gaucher's disease patients. Hum Mutat. 1996;7(3):272-4.
8889578	Beutler E, Gelbart T: Glucocerebrosidase (Gaucher disease). Hum Mutat. 1996;8(3):207-13.
8889591	Amaral O, Pinto E, Fortuna M, Lacerda L, Sa Miranda MC: Type 1 Gaucher disease: identification of N396T and prevalence of glucocerebrosidase mutations in the Portuguese. Hum Mutat. 1996;8(3):280-1.
8937765	Morar B, Lane AB: The molecular characterization of Gaucher disease in South Africa. Clin Genet. 1996 Aug;50(2):78-84.
9040001	Uyama E, Uchino M, Ida H, Eto Y, Owada M: D409H/D409H genotype in Gaucher-like disease. J Med Genet. 1997 Feb;34(2):175.
9061570	Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y: Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis. 1997 Mar;20(1):67-73.
9153297	Grace ME, Desnick RJ, Pastores GM: Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients. J Clin Invest. 1997 May 15;99(10):2530-7.
9182788	Cormand B, Grinberg D, Gort L, Fiumara A, Barone R, Vilageliu L, Chabas A: Two new mild homozygous mutations in Gaucher disease patients: clinical signs and biochemical analyses. Am J Med Genet. 1997 Jun 27;70(4):437-43.
9217217	Choy FY, Humphries ML, Shi H: Identification of two novel and four uncommon missense mutations among chinese Gaucher disease patients. Am J Med Genet. 1997 Aug 8;71(2):172-8.
9279145	Hatton CE, Cooper A, Whitehouse C, Wraith JE: Mutation analysis in 46 British and Irish patients with Gaucher's disease. Arch Dis Child. 1997 Jul;77(1):17-22.
9331372	Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E: Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res. 1997 Oct;7(10):1020-6.
9516376	Beutler E, Gelbart T: Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis. 1998 Mar;24(1):2-8.
9554454	Demina A, Beutler E: Six new Gaucher disease mutations. Acta Haematol. 1998;99(2):80-2.
9554746	Cormand B, Grinberg D, Gort L, Chabas A, Vilageliu L: Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat. 1998;11(4):295-305.
9637431	Choy FY, Humphries ML, Ben-Yoseph Y: Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient. Am J Med Genet. 1998 Jun 16;78(1):92-3.
9650766	Parenti G, Filocamo M, Titomanlio L, Rizzolo G, Silvestro E, Perretti A, Gatti R, Andria G: A novel mutation of the beta-glucocerebrosidase gene associated with neurologic manifestations in three sibs. Clin Genet. 1998 Apr;53(4):281-5.
9683600	Germain DP, Puech JP, Caillaud C, Kahn A, Poenaru L: Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease. Am J Hum Genet. 1998 Aug;63(2):415-27.
9851895	Sinclair G, Choy FY, Humphries L: A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Blood Cells Mol Dis. 1998 Dec;24(4):420-7.

# Drug_Target_6_HGNC_ID:
HGNC:4177

# Drug_Target_6_HPRD_ID:
06973

# Drug_Target_6_ID:
1373

# Drug_Target_6_Locus:
1q21

# Drug_Target_6_Molecular_Weight:
59717

# Drug_Target_6_Name:
Glucosylceramidase

# Drug_Target_6_Number_of_Residues:
536

# Drug_Target_6_PDB_ID:
1Y7V

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF02055	Glyco_hydro_30

# Drug_Target_6_Protein_Sequence:
>Glucosylceramidase precursor
MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNAT
YCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGF
GGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDD
FQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQP
GDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIA
RDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAK
ATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDW
NLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQK
NDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ

# Drug_Target_6_Reaction:
D-glucosyl-N-acylsphingosine + H2O = D-glucose + N-acylsphingosine

# Drug_Target_6_Signals:
21-39

# Drug_Target_6_Specific_Function:
D-glucosyl-N-acylsphingosine + H(2)O = D- glucose + N-acylsphingosine

# Drug_Target_6_SwissProt_ID:
P04062

# Drug_Target_6_SwissProt_Name:
GLCM_HUMAN

# Drug_Target_6_Synonyms:
Acid beta-glucosidase
Alglucerase
Beta-glucocerebrosidase
D-glucosyl-N-acylsphingosine glucohydrolase
EC 3.2.1.45
Glucosylceramidase precursor
Imiglucerase

# Drug_Target_6_Theoretical_pI:
7.66

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasmic

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
D83967

# Drug_Target_7_GenBank_ID_Protein:
2626811

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
pdaA

# Drug_Target_7_Gene_Sequence:
>792 bp
TTACAAAGACGGCAGCCTCATTTCTTTCTCAAACATCAGATCATCAATGCTTTTAAAAGT
GTAGCCCTGTTTTTTCAGATCTGTAATCGCGTCATCCAGCGCTTCTGCATTGTCCCTCGA
TACGGTGTGAAGCAGGTAAATGGCTCCCGGGTGCGCCTGCTTGATCATATGATCGTAGGC
ATATTTCTTTCCCTTTTGGTTGTTGATTTTCCAATCAACAAAAGCGACCGACCAGAAAAC
GGTTTGATAGCCGAGGCGTTTCGTTTCTTTCAGTACGTACTCACTGAACACGCCGCGCGG
CGGACGCAAATACAGGTTGTCCTGCTTTCCCGTAATTTTATAAACCTCTTCGTTGACTGA
ATCAAGTTCATCCTGAATCTGATCAGCTGTTTTTGTCGTTAAATCCGGATGGTGAAAGGA
ATGATTGCCGATAATATGGCCCTCATCTGACATTCGTTTGATCAGCTGAGGCTGGTCCTT
TACGAAATGCCCGGTGACAAAAAACGTTCCTGTTACGCGATGTTTTTTTAAGACATCAAG
CACTTTTGGCGTATAGCCATTTTCATATCCGTTATCAAACGTTAAGTAAATCGTTTTTTC
CTTTGTATTCCCTAAATAAAACGCGTCATATTTTTCAATTAAACTGTTCAGCTGCTTCCC
GGCATCTGGCGGCTGATGATTGACACTTCGTTTAAAGCCCCAATTAATCGGCTCATTCGG
CACCGCTTCCGCCTGTGCTGCACCTCCGGCAAGCAATACGGCGGCGCAGCATATTGAACA
CATCCACTTCAT

# Drug_Target_7_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_7_General_References:
12374835	Fukushima T, Yamamoto H, Atrih A, Foster SJ, Sekiguchi J: A polysaccharide deacetylase gene (pdaA) is required for germination and for production of muramic delta-lactam residues in the spore cortex of Bacillus subtilis. J Bacteriol. 2002 Nov;184(21):6007-15.
8969503	Yamamoto H, Uchiyama S, Sekiguchi J: Cloning and sequencing of a 40.6 kb segment in the 73 degrees-76 degrees region of the Bacillus subtilis chromosome containing genes for trehalose metabolism and acetoin utilization. Microbiology. 1996 Nov;142 ( Pt 11):3057-65.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
3626

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
30070

# Drug_Target_7_Name:
Probable polysaccharide deacetylase pdaA

# Drug_Target_7_Number_of_Residues:
263

# Drug_Target_7_PDB_ID:
1W17

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01522	Polysacc_deac_1

# Drug_Target_7_Protein_Sequence:
>Probable polysaccharide deacetylase pdaA precursor
MKWMCSICCAAVLLAGGAAQAEAVPNEPINWGFKRSVNHQPPDAGKQLNSLIEKYDAFYL
GNTKEKTIYLTFDNGYENGYTPKVLDVLKKHRVTGTFFVTGHFVKDQPQLIKRMSDEGHI
IGNHSFHHPDLTTKTADQIQDELDSVNEEVYKITGKQDNLYLRPPRGVFSEYVLKETKRL
GYQTVFWSVAFVDWKINNQKGKKYAYDHMIKQAHPGAIYLLHTVSRDNAEALDDAITDLK
KQGYTFKSIDDLMFEKEMRLPSL

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-23

# Drug_Target_7_Specific_Function:
Required for production of muramic delta-lactam residues in the spore cortex and for germination

# Drug_Target_7_SwissProt_ID:
O34928

# Drug_Target_7_SwissProt_Name:
PDAA_BACSU

# Drug_Target_7_Synonyms:
EC 3.-.-.-
Probable polysaccharide deacetylase pdaA precursor

# Drug_Target_7_Theoretical_pI:
7.70

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
SIGLEC7

# Drug_Target_8_GenBank_ID_Gene:
AF170485

# Drug_Target_8_GenBank_ID_Protein:
6466012

# Drug_Target_8_GeneCard_ID:
SIGLEC7

# Drug_Target_8_Gene_Name:
SIGLEC7

# Drug_Target_8_Gene_Sequence:
>1404 bp
ATGCTGCTGCTGCTGCTGCTGCCCCTGCTCTGGGGGAGGGAGAGGGTGGAAGGACAGAAG
AGTAACCGGAAGGATTACTCGCTGACGATGCAGAGTTCCGTGACCGTGCAAGAGGGCATG
TGTGTCCATGTGCGCTGCTCCTTCTCCTACCCAGTGGACAGCCAGACTGACTCTGACCCA
GTTCATGGCTACTGGTTCCGGGCAGGGAATGATATAAGCTGGAAGGCTCCAGTGGCCACA
AACAACCCAGCTTGGGCAGTGCAGGAGGAAACTCGGGACCGATTCCACCTCCTTGGGGAC
CCACAGACCAAAAATTGCACCCTGAGCATCAGAGATGCCAGAATGAGTGATGCGGGGAGA
TACTTCTTTCGTATGGAGAAAGGAAATATAAAATGGAATTATAAATATGACCAGCTCTCT
GTGAACGTGACAGCCTTGACCCACAGGCCCAACATCCTTATCCCCGGTACCCTGGAGTCT
GGCTGCTTCCAGAATCTGACCTGCTCTGTGCCCTGGGCCTGTGAGCAGGGGACGCCCCCT
ATGATCTCCTGGATGGGGACCTCTGTGTCCCCCCTGCACCCCTCCACCACCCGCTCCTCA
GTGCTCACCCTCATCCCACAGCCCCAGCACCACGGCACCAGCCTCACCTGTCAGGTGACC
TTGCCTGGGGCCGGCGTGACCACGAACAGGACCATCCAACTCAATGTGTCCTACCCTCCT
CAGAACTTGACTGTGACTGTCTTCCAAGGAGAAGGCACAGCATCCACAGCTCTGGGGAAC
AGCTCATCTCTTTCAGTCCTAGAGGGCCAGTCTCTGCGCTTGGTCTGTGCTGTTGACAGC
AATCCCCCTGCCAGGCTGAGCTGGACCTGGAGGAGTCTGACCCTGTACCCCTCACAGCCC
TCAAACCCTCTGGTACTGGAGCTGCAAGTGCACCTGGGGGATGAAGGGGAATTCACCTGT
CGAGCTCAGAACTCTCTGGGTTCCCAGCACGTTTCCCTGAACCTCTCCCTGCAACAGGAG
TACACAGGCAAAATGAGGCCTGTATCAGGAGTGTTGCTGGGGGCGGTCGGGGGAGCTGGA
GCCACAGCCCTGGTCTTCCTCTCCTTCTGTGTCATCTTCATTGTAGTGAGGTCCTGCAGG
AAGAAATCGGCAAGGCCAGCAGCGGACGTGGGAGACATAGGCATGAAGGATGCAAACACC
ATCAGGGGCTCAGCCTCTCAGGGTAACCTGACTGAGTCCTGGGCAGATGATAACCCCCGA
CACCATGGCCTGGCTGCCCACTCCTCAGGGGAGGAAAGAGAGATCCAGTATGCACCCCTC
AGCTTTCATAAGGGGGAGCCTCAGGACCTATCAGGTCAAGAAGCCACCAACAATGAGTAC
TCAGAGATCAAGATCCCCAAGTAA

# Drug_Target_8_General_Function:
Involved in sugar binding activity

# Drug_Target_8_General_References:
10499918	Falco M, Biassoni R, Bottino C, Vitale M, Sivori S, Augugliaro R, Moretta L, Moretta A: Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J Exp Med. 1999 Sep 20;190(6):793-802.
10567377	Nicoll G, Ni J, Liu D, Klenerman P, Munday J, Dubock S, Mattei MG, Crocker PR: Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem. 1999 Nov 26;274(48):34089-95.
10611343	Vitale C, Romagnani C, Falco M, Ponte M, Vitale M, Moretta A, Bacigalupo A, Moretta L, Mingari MC: Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15091-6.
10764831	Angata T, Varki A: Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology. 2000 Apr;10(4):431-8.
11389909	Ito A, Handa K, Withers DA, Satoh M, Hakomori S: Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett. 2001 Jun 1;498(1):116-20.

# Drug_Target_8_HGNC_ID:
HGNC:10876

# Drug_Target_8_HPRD_ID:
05102

# Drug_Target_8_ID:
2998

# Drug_Target_8_Locus:
19q13.3

# Drug_Target_8_Molecular_Weight:
51143

# Drug_Target_8_Name:
Sialic acid-binding Ig-like lectin 7

# Drug_Target_8_Number_of_Residues:
467

# Drug_Target_8_PDB_ID:
1NKO

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00047	ig
PF07686	V-set
PF08205	C2-set_2

# Drug_Target_8_Protein_Sequence:
>Sialic acid-binding Ig-like lectin 7 precursor
MLLLLLLPLLWGRERVEGQKSNRKDYSLTMQSSVTVQEGMCVHVRCSFSYPVDSQTDSDP
VHGYWFRAGNDISWKAPVATNNPAWAVQEETRDRFHLLGDPQTKNCTLSIRDARMSDAGR
YFFRMEKGNIKWNYKYDQLSVNVTALTHRPNILIPGTLESGCFQNLTCSVPWACEQGTPP
MISWMGTSVSPLHPSTTRSSVLTLIPQPQHHGTSLTCQVTLPGAGVTTNRTIQLNVSYPP
QNLTVTVFQGEGTASTALGNSSSLSVLEGQSLRLVCAVDSNPPARLSWTWRSLTLYPSQP
SNPLVLELQVHLGDEGEFTCRAQNSLGSQHVSLNLSLQQEYTGKMRPVSGVLLGAVGGAG
ATALVFLSFCVIFIVVRSCRKKSARPAADVGDIGMKDANTIRGSASQGNLTESWADDNPR
HHGLAAHSSGEEREIQYAPLSFHKGEPQDLSGQEATNNEYSEIKIPK

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-18

# Drug_Target_8_Specific_Function:
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha2,3 and alpha2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro)

# Drug_Target_8_SwissProt_ID:
Q9Y286

# Drug_Target_8_SwissProt_Name:
SIGL7_HUMAN

# Drug_Target_8_Synonyms:
AIRM-1
Adhesion inhibitory receptor molecule 1
CD328 antigen
CDw328
D-siglec
QA79 membrane protein
Sialic acid-binding Ig-like lectin 7 precursor
Siglec-7
p75

# Drug_Target_8_Theoretical_pI:
7.32

# Drug_Target_8_Transmembrane_Regions:
354-376

# Drug_Target_9_Cellular_Location:
Membrane
single-pass type II membrane protein

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
X04355

# Drug_Target_9_GenBank_ID_Protein:
60936

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
HN

# Drug_Target_9_Gene_Sequence:
>1734 bp
ATGGACCGCGCAGTTAGCCAAGTTGCGTTAGAGAATGATGAAAGAGAGGCAAAAAATACA
TGGCGCTTGATATTCCGGATTGCAATCTTACTCTTAACAGTAGTGACCTTAGCTACATCT
GTAGCCTCCCTTGTATATAGCATGGGGGCTAGCACACCTAGCGACCTTGTAGGCATACCG
ACCAGGATTTCTAGGGCAGAAGAAAAGATTACATCTGCACTTGGTTCCAATCAAGATGTA
GTAGATAGGATATATAAGCAAGTGGCCCTTGAGTCTCCGTTGGCATTGTTAAACACTGAG
ACCACAATTATGAACGCAATAACATCTCTCTCTTATCAGATTAATGGAGCTGCGAACAAC
AGCGGGTGGGGGGCACCTATCCATGACCCAGATTTTATCGGGGGGATAGGCAAAGAACTC
ATTGTAGATGATGCTAGTGATGTCACATCATTCTATCCCTCTGCATTTCAAGAACATCTG
AATTTTATCCCGGCGCCTACTACAGGATCAGGTTGCACTCGGATACCTTCATTTGACATG
AGTGCTACCCATTACTGCTACACTCATAATGTAATATTGTCTGGATGCAGAGATCACTCA
CACTCACATCAGTATTTAGCACTTGGTGTGCTCCGGACAACTGCAACAGGGAGGATATTC
TTTTCTACTCTGCGTTCCATCAGTCTGGATGACACCCAAAATCGGAAGTCTTGCAGTGTG
AGTGCAACTCCCTTAGGTTGTGATATGCTGTGCTCGAAAGTCACGGAGACAGAGGAAGAA
GATTATAACTCAGCTGTCCCTACGCTGATGGCACATGGGAGGTTAGGGTTCGACGGCCAA
TACCACGAAAAGGACCTAGACGTCACAACATTATTTGAGGACTGGGTGGCCAACTACCCA
GGAGTAGGGGGTGGATCTTTTATTGACGGCCGCGTATGGTTCTCAGTCTACGGAGGGCTG
AAACCCAATTCACCCAGTGACACTGTACAGGAAGGGAAATATGTAATATACAAGCGATAC
AATGACACATGCCCAGATGAGCAAGACTACCAGATCCGAATGGCCAAGTCTTCGTATAAG
CCCGGGCGGTTTGGTGGGAAACGCATACAGCAGGCTATCTTATCTATCAAGGTGTCAACA
TCTTTGGGCGAAGACCCAGTACTGACTGTACCGCCCAACACAGTCACACTCATGGGGGCC
GAAGGCAGAATTCTCACAGTAGGGACATCTCATTTCTTGTATCAGCGAGGGTCATCATAC
TTCTCTCCCGCGTTATTATATCCTATGACAGTCAGCAACAAAACAGCCACTCTTCATAGT
CCCTATACATTCAATGCCTTCACTCGGCCAGGTAGTATCCCTTGCCAGGCTTCAGCAAGA
TGCCCCAACTCGTGTGTTACTGGAGTCTATACAGATCCATATCCCCTAATCTTCTATAGG
AACCACACCTTGCGAGGGGTATTCGGGACAATGCTTGATAGTGAACAAGCAAGACTTAAT
CCTACGTCTGCAGTATTCGATAGCACATCCCGCAGTCGCATAACTCGAGTGAGTTCAAGC
AGCACCAAAGCAGCATACACAACATCAACTTGTTTTAAAGTTGTCAAGACCAATAAGACC
TATTGTCTCAGCATTGCTGAAATATCTAATACTCTCTTCGGAGAATTCAGAATCGTCCCG
TTACTAGTTGAGATCCTCAAAAATGATGGGGTTAGAGAAGCCAGGTCTGGTTAG

# Drug_Target_9_General_Function:
Not Available

# Drug_Target_9_General_References:
2705297	Sakaguchi T, Toyoda T, Gotoh B, Inocencio NM, Kuma K, Miyata T, Nagai Y: Newcastle disease virus evolution. I. Multiple lineages defined by sequence variability of the hemagglutinin-neuraminidase gene. Virology. 1989 Apr;169(2):260-72.
3018130	Millar NS, Chambers P, Emmerson PT: Nucleotide sequence analysis of the haemagglutinin-neuraminidase gene of Newcastle disease virus. J Gen Virol. 1986 Sep;67 ( Pt 9):1917-27.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3609

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
63143

# Drug_Target_9_Name:
Hemagglutinin-neuraminidase

# Drug_Target_9_Number_of_Residues:
577

# Drug_Target_9_PDB_ID:
1USR

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00423	HN

# Drug_Target_9_Protein_Sequence:
>Hemagglutinin-neuraminidase
MDRAVSQVALENDEREAKNTWRLIFRIAILLLTVVTLATSVASLVYSMGASTPSDLVGIP
TRISRAEEKITSALGSNQDVVDRIYKQVALESPLALLNTETTIMNAITSLSYQINGAANN
SGWGAPIHDPDFIGGIGKELIVDDASDVTSFYPSAFQEHLNFIPAPTTGSGCTRIPSFDM
SATHYCYTHNVILSGCRDHSHSHQYLALGVLRTTATGRIFFSTLRSISLDDTQNRKSCSV
SATPLGCDMLCSKVTETEEEDYNSAVPTLMAHGRLGFDGQYHEKDLDVTTLFEDWVANYP
GVGGGSFIDGRVWFSVYGGLKPNSPSDTVQEGKYVIYKRYNDTCPDEQDYQIRMAKSSYK
PGRFGGKRIQQAILSIKVSTSLGEDPVLTVPPNTVTLMGAEGRILTVGTSHFLYQRGSSY
FSPALLYPMTVSNKTATLHSPYTFNAFTRPGSIPCQASARCPNSCVTGVYTDPYPLIFYR
NHTLRGVFGTMLDSEQARLNPTSAVFDSTSRSRITRVSSSSTKAAYTTSTCFKVVKTNKT
YCLSIAEISNTLFGEFRIVPLLVEILKNDGVREARSG

# Drug_Target_9_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Neuraminidase activity ensures the efficient spread of the virus by dissociating the mature virions from the neuraminic acid containing glycoproteins

# Drug_Target_9_SwissProt_ID:
P32884

# Drug_Target_9_SwissProt_Name:
HN_NDVB

# Drug_Target_9_Synonyms:
EC 3.2.1.18

# Drug_Target_9_Theoretical_pI:
7.09

# Drug_Target_9_Transmembrane_Regions:
27-48

#END_DRUGCARD DB03740
